Four report types, one methodology

Who controls which cohort, and on what evidence. Drug-by-drug commercial posture, prescribing share and payer positioning.

Disease burden, diagnosis rates and the treatment pathway. The market map you build commercial strategy on.

An incidence-to-eligible funnel built as a live, re-runnable Excel model: 8 sheets, 119 formulas, zero hardcoded cells. Every conversion step sourced, every assumption editable.

Coverage criteria and the evidence standard. How payers and HTA bodies evaluate access and step-edits.

How the prescriber base, reimbursement channel and targeting gate should shape field deployment. Account depth vs. reach, channel coverage, and territory design.

The competitive, epidemiological, and payer-readiness case for entering a market before launch. What a pre-launch asset needs to prove, size, and prepare for.

A six-sheet KOL universe and engagement workbook, built gate by gate: sizing, tier classification, scientific influence, engagement readiness, MSL territory coverage, and cross-border network. Every KOL entry carries a verification tag.

A 12-sheet pricing architecture built market by market: price ladder, international reference-price basket, value-based ICER, gross-to-net waterfall, launch sequencing, and revenue scenarios — not a single number, a re-runnable model.

A static, triangulated patient-count model, not a forecast: 5-sheet workbook (Cover, Model, Research Validation, QC, Sensitivity), every input sourced and re-runnable. Sizing answers how many patients exist today; forecasting is a separate question.

A 9-sheet HTA submission-strategy model: authority landscape, PICO framework, comparator defence, value-dossier self-assessment, HEOR gap register, and submission timeline — built before the dossier is written, not after.